644 related articles for article (PubMed ID: 10742300)
1. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
Sugidachi A; Asai F; Ogawa T; Inoue T; Koike H
Br J Pharmacol; 2000 Apr; 129(7):1439-46. PubMed ID: 10742300
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.
Niitsu Y; Jakubowski JA; Sugidachi A; Asai F
Semin Thromb Hemost; 2005 Apr; 31(2):184-94. PubMed ID: 15852222
[TBL] [Abstract][Full Text] [Related]
3. Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747.
Sugidachi A; Asai F; Yoneda K; Iwamura R; Ogawa T; Otsuguro K; Koike H
Br J Pharmacol; 2001 Jan; 132(1):47-54. PubMed ID: 11156560
[TBL] [Abstract][Full Text] [Related]
4. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
[TBL] [Abstract][Full Text] [Related]
5. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite.
Sugidachi A; Ogawa T; Kurihara A; Hagihara K; Jakubowski JA; Hashimoto M; Niitsu Y; Asai F
J Thromb Haemost; 2007 Jul; 5(7):1545-51. PubMed ID: 17456192
[TBL] [Abstract][Full Text] [Related]
6. Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability.
Wong PC; Crain EJ; Watson CA; Hua J; Schumacher WA; Rehfuss R
Thromb Haemost; 2009 Jan; 101(1):108-15. PubMed ID: 19132196
[TBL] [Abstract][Full Text] [Related]
7. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
[TBL] [Abstract][Full Text] [Related]
8. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.
Hasegawa M; Sugidachi A; Ogawa T; Isobe T; Jakubowski JA; Asai F
Thromb Haemost; 2005 Sep; 94(3):593-8. PubMed ID: 16268477
[TBL] [Abstract][Full Text] [Related]
9. Binding of [3H]-2-methylthio ADP to rat platelets--effect of clopidogrel and ticlopidine.
Savi P; Laplace MC; Maffrand JP; Herbert JM
J Pharmacol Exp Ther; 1994 May; 269(2):772-7. PubMed ID: 8182545
[TBL] [Abstract][Full Text] [Related]
10. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.
Savi P; Herbert JM
Semin Thromb Hemost; 2005 Apr; 31(2):174-83. PubMed ID: 15852221
[TBL] [Abstract][Full Text] [Related]
11. A novel P2Y(12) adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models.
Wang YX; Vincelette J; da Cunha V; Martin-McNulty B; Mallari C; Fitch RM; Alexander S; Islam I; Buckman BO; Yuan S; Post JM; Subramanyam B; Vergona R; Sullivan ME; Dole WP; Morser J; Bryant J
Thromb Haemost; 2007 May; 97(5):847-55. PubMed ID: 17479197
[TBL] [Abstract][Full Text] [Related]
12. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro.
Weber AA; Reimann S; Schrör K
Br J Pharmacol; 1999 Jan; 126(2):415-20. PubMed ID: 10077233
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats.
Sugidachi A; Ohno K; Ogawa T; Jakubowski J; Hashimoto M; Tomizawa A
Br J Pharmacol; 2013 May; 169(1):82-9. PubMed ID: 23347039
[TBL] [Abstract][Full Text] [Related]
14. Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.
van Giezen JJ; Berntsson P; Zachrisson H; Björkman JA
Thromb Res; 2009 Nov; 124(5):565-71. PubMed ID: 19692114
[TBL] [Abstract][Full Text] [Related]
15. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits.
Wong PC; Crain EJ; Watson CA; Jiang X; Hua J; Bostwick JS; Ogletree ML; Schumacher WA; Rehfuss R
J Cardiovasc Pharmacol; 2007 May; 49(5):316-24. PubMed ID: 17513951
[TBL] [Abstract][Full Text] [Related]
16. Biomarker optimization to track the antithrombotic and hemostatic effects of clopidogrel in rats.
Schumacher WA; Bostwick JS; Ogletree ML; Stewart AB; Steinbacher TE; Hua J; Price LA; Wong PC; Rehfuss RP
J Pharmacol Exp Ther; 2007 Jul; 322(1):369-77. PubMed ID: 17420297
[TBL] [Abstract][Full Text] [Related]
17. Comparison of antiplatelet effects of prasugrel and ticagrelor in cynomolgus monkeys by an ELISA-based VASP phosphorylation assay and platelet aggregation.
Tomizawa A; Ohno K; Jakubowski JA; Mizuno M; Sugidachi A
Thromb Haemost; 2013 Oct; 110(4):769-76. PubMed ID: 23903326
[TBL] [Abstract][Full Text] [Related]
18. P2Y12, a new platelet ADP receptor, target of clopidogrel.
Herbert JM; Savi P
Semin Vasc Med; 2003 May; 3(2):113-22. PubMed ID: 15199474
[TBL] [Abstract][Full Text] [Related]
19. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function.
Dovlatova NL; Jakubowski JA; Sugidachi A; Heptinstall S
J Thromb Haemost; 2008 Jul; 6(7):1153-9. PubMed ID: 18485086
[TBL] [Abstract][Full Text] [Related]
20. Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors.
Gachet C; Cattaneo M; Ohlmann P; Hechler B; Lecchi A; Chevalier J; Cassel D; Mannucci PM; Cazenave JP
Br J Haematol; 1995 Oct; 91(2):434-44. PubMed ID: 8547091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
